IL6 and respiratory tract infectious disorder: Due to the ineffectiveness of IL‐6 modulatory therapies such as tocilizumab (Lokau, Kleinegger, et al., 2020; Lokau, Waetzig, et al., 2020; Okazaki et al., 2002) in mouse models, we also used IL‐6‐deficient mice to model IL‐6 inhibition during respiratory infection.